Vertex Pharmaceuticals (VRTX) Cash from Financing Activities (2009 - 2026)

Vertex Pharmaceuticals has reported Cash from Financing Activities for 18 years, with the latest figure at -$538.8 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Financing Activities rose 20.81% year-over-year to -$538.8 million; the trailing twelve-month figure through Mar 2026 stood at -$2.1 billion (down 16.61% YoY), and the FY2025 full-year result was -$2.3 billion, down 51.27% from the prior year.
• Cash from Financing Activities for Q1 2026 stood at -$538.8 million, down from -$77.2 million in the prior quarter.
• The five-year high for Cash from Financing Activities was $47.7 million in Q2 2022, with the low at -$1.2 billion in Q3 2025.
• Average Cash from Financing Activities over 5 years is -$289.7 million, with a median of -$294.7 million recorded in 2023.
• Year-over-year, Cash from Financing Activities surged 111.96% in 2022 and sank 2172.83% in 2024.
• Tracing VRTX's Cash from Financing Activities over 5 years: stood at $40.2 million in 2022, then plunged by 398.01% to -$119.8 million in 2023, then tumbled by 226.63% to -$391.3 million in 2024, then surged by 80.27% to -$77.2 million in 2025, then slumped by 597.93% to -$538.8 million in 2026.
• The last three Cash from Financing Activities figures came in at -$538.8 million (Q1 2026), -$77.2 million (Q4 2025), and -$1.2 billion (Q3 2025), per Business Quant data.

Peer Comparison